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Abstract
Aims/hypothesis Identifying rare coding variants associated with albuminuria may open new avenues for preventing chronic
kidney disease and end-stage renal disease, which are highly prevalent in individuals with diabetes. Efforts to identify genetic
susceptibility variants for albuminuria have so far been limited, with the majority of studies focusing on common variants.
Methods We performed an exome-wide association study to identify coding variants in a two-stage (discovery and replication)
approach. Data from 33,985 individuals of European ancestry (15,872 with and 18,113 without diabetes) and 2605 Greenlanders
were included.
Results We identified a rare (minor allele frequency [MAF]: 0.8%) missense (A1690V) variant in CUBN (rs141640975, β = 0.27,
p = 1.3 × 10−11) associated with albuminuria as a continuous measure in the combined European meta-analysis. The presence of
each rare allele of the variant was associatedwith a 6.4% increase in albuminuria. The rareCUBN variant had an effect that was three
times stronger in individuals with type 2 diabetes compared with those without (pinteraction = 7.0 × 10
−4, β with diabetes = 0.69, β
without diabetes = 0.20) in the discovery meta-analysis. Gene-aggregate tests based on rare and common variants identified three
additional genes associated with albuminuria (HES1, CDC73 and GRM5) after multiple testing correction (pBonferroni < 2.7 × 10
−6).
Conclusions/interpretation The current study identifies a rare coding variant in the CUBN locus and other potential genes
associated with albuminuria in individuals with and without diabetes. These genes have been implicated in renal and cardiovas-
cular dysfunction. The findings provide new insights into the genetic architecture of albuminuria and highlight target genes and
pathways for the prevention of diabetes-related kidney disease.
Keywords Albuminuria . Diabetes . DKD . Exome chip . Genetics . Genome-wide association study . Kidney disease . GWAS .
Rare variant . SKAT . Type 2 diabetes
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combined meta-analysis)
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Introduction
Albuminuria is a manifestation of chronic kidney disease
(CKD), a major health burden worldwide with a current prev-
alence of 14.8% in the USA [1]. In individuals with CKD,
changes in albuminuria are strongly associated with the risk
of end-stage renal disease and death [2]. Diabetic individuals
have an increased risk of developing CKD (referred to as dia-
betic kidney disease [DKD]); in the USA, the prevalence of
CKD is ~41% among individuals with diabetes in comparison
with ~10% in individuals without diabetes [3]. DKD proceeds
in stages: (1) an increase in albuminuria (or microalbuminuria,
30 to 300 mg/g urinary albumin); (2) progressing to
macroalbuminuria or proteinuria (>300 mg/g); (3) loss of kid-
ney function (GFR < 30 ml/min); and finally (4) requiring re-
nal replacement. Recent evidence suggests a new facet of
nephron function, with the proximal tubule playing a part in
DKD pathophysiology [4] in addition to having a role as a
filtration barrier in glomerular haemodynamics.
DKD development may be primarily determined by proxi-
mal tubule injury, which is connected to glomerulus
hyperfiltration and glomerular barrier damage via mechanisms
modulating albumin excretion and re-uptake [4]. Glomerular
hyperfiltration, which occurs early in the course of DKD, is
augmented by the hyperglycaemic state in diabetes via in-
creased filtering of glucose. This stimulates the proximal tubule
to reabsorb glucose which, coupled with sodium reabsorption,
results in vasorelaxation of the afferent artery and increased
renal blood flow [5]. Albuminuria is a pivotal biomarker among
diabetic individuals who develop DKD, reflecting glomerular
and tubular dysfunction [6]. It may also reflect a generalised
endothelial dysfunction and is associated with an increased risk
of cardiovascular events in diabetic individuals [7, 8].
Family studies suggest that genetic factors explain 16–49%
of albuminuria [9]. While several genome-wide association
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studies (GWASs) of albuminuria have been performed to date,
most have focused on identifying common genetic variants
(minor allele frequency [MAF] ≥ 5%) for albuminuria
[10–12]. Recently, we identified rare coding variants for kid-
ney function (estimated GFR [eGFR]) and development in an
exome-wide association study (ExWAS) [13]. Here, we used a
similar approach to identify rare (MAF < 1%) or low-
frequency (MAF 1–5%) coding variants for albuminuria in
33,985 individuals of European ancestry with (n = 15,872)
and without (n = 18,113) diabetes.
Methods
Study populations
The present study comprises a two-stage design: discovery
and replication. The discovery set includes five cohorts
from Denmark (Inter99, Health2006, Health2008, Vejle
Biobank and the Anglo–Danish–Dutch Study of Intensive
Treatment In People with Screen Detected Diabetes in
Primary Care (Addition)-DK, [Table 1]), with a total of
13,226 participants (3896 with and 9330 without type 2
diabetes), as described previously [14, 15] (electronic sup-
plementary material [ESM] Methods 1.1 Discovery Phase).
The first three are population based while the last two are
type 2 diabetes case cohorts.
The replication set includes multiple studies of
European descent (n = 20,759) involving 11,976 individ-
uals with and 8783 without diabetes (Table 1). These com-
prise the Danish study of functional disorders (DanFunD)
[16], Malmö Diet and Cancer Study (MDCS) [17],
Genesis/Genediab [18], Innovative Medicines Initiative –
Surrogate markers for Micro- and Macro-vascular hard
endpoints for Innovative diabetes Tools (IMI-SUMMIT)
Consortia (Europe/UK-based consortia on diabetes stud-
ies) [19] and Greenlandic Inuit populations (n = 2605)
[20]. The DanFunD, MDCS and Greenlandic studies were
population based, whereas the Genesis/Genediab studies
involved people with type 1 diabetes and the IMI-
SUMMIT comprised four type 1 and five type 2 diabetes
studies. All studies are described in ESM Methods 1.2
Replication Phase.
None of the studies overlapped with the previous albumin-
uria GWASs except two replication cohorts within the IMI-
SUMMIT Consortia (Finnish Diabetic Nephropathy Study
[FinnDiane] and Scania Diabetes Register) that participated
in the type 1 diabetes albuminuria GWAS [12].
The present study was conducted in accordance with the
Helsinki Declaration and all the participating studies were
approved by their respective data protection boards and by
the regional scientific ethics committees. Informed consent
from all participants was obtained.
Albuminuria measurements
Albuminuria was diagnosed from a 24 h urine collection
(mg/24 h), also called the urinary albumin excretion rate
(AER) or from spot urine samples measuring urinary albu-
min and creatinine concentrations and calculating the uri-
nary albumin/creatinine ratio (ACR in mg/mmol). The
summary measures for AER and ACR in the participating
cohorts have been described in Table 1 and methods de-
scribed in ESM Table 1.
Genotyping and SNP quality control
Genotyping of the discovery stage studies was performed on
the Illumina HumanExome BeadChip 12V.1.0 containing
263,894 single nucleotide polymorphisms (SNPs) and includ-
ing an additional 16,340 custom-typed SNPs from the Danish
Exome Sequencing Project as described previously [14, 21]
and briefly in ESM Methods 1.3 Danish Exome Sequencing
based SNP Selection. Most SNPs were exome based (non-
synonymous/coding) gene variants (~90%); thus, we refer to
the present association study as an ExWAS. Genotype calling
on the discovery set cohorts was performed using the Illumina
GenCall plus the zCall algorithm to improve rare variant call-
ing [22]. We excluded SNPs based on: (1) cluster separation
score <0.4; (2) Hardy–Weinberg equilibrium p < 10−6; and (3)
call rate <98%. We also excluded individuals with: (1) sex
mismatches; (2) genetic duplicates; (3) call rate <95%; and
(4) no clustering with the European-ancestry-specific SNPs
through a principal component analyses (PCA) approach
seeded with ancestry informative markers (AIMs), as de-
scribed previously [23]. After quality control, a total of
142,397 SNPs remained for a total of 13,226 individuals with
complete phenotype and genotype data in the discovery set.
Details of the replication cohorts are provided in ESMTable 2.
All SNP positions are based on the Genome Reference
Consortium Human Build 37 (GRCh37) of dbSNP (https://
www.ncbi.nlm.nih.gov/assembly/GCF_000001405.13/).
One replication (MDCS) cohort used Illumina Exome
array-based genotyped data, the Greenlandic cohort used
Illumina Metabochip-based genotype data [20] while other
cohorts had SNP data available from exome-/genome-wide
array imputation.
Statistical analyses
Discovery stage The discovery stage exome-wide association
analysis was first performed in each of the five participating
studies individually using additive linear regression model
and adjusting for sex, age and population sub-structure
(principal components; see Project analyses plan in ESM
Methods 1.4). Albuminuria measures were natural-log trans-
formed to correct for non-normalised data. The study-specific
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results were meta-analysed using inverse variance-weighted
fixed-effects meta-analysis with weights proportional to the
squared standard errors of the effect estimates. The genomic
inflation factor (λ) was at acceptable levels both in the
individual association analysis (λInter99 = 1.01, λHealth2006 =
1.0, λHealth2008 = 1.0, λVejle = 0.99, λAddition-DK = 1.01) and in
the combined discovery meta-exome-wide association analy-
sis (λdiscovery = 1.0). A χ
2 test for heterogeneity was
Table 1 Clinical characteristics of the individual cohorts: pooled and stratified on diabetes status: discovery and replication stages
Study name Sample
set type
n Women, % Age, years ACRa (mg/mmol)
or AERb (mg/24 h)
Diabetes, % Diabetes
type
Diabetes
duration,
years
Stage 1 (discovery)
Addition-DKa All 2013 47.3 59.6 (7.0) 0.6 (0.2–1.59)a 81.6 Type 2 –
DM 1643 43.9 60.1 (6.8) 0.6 (0.2–1.7)a –
Non-DM 370 62.4 57.6 (7.4) 0.5 (0.2–1.39)a –
Health2006a All 2658 51.3 49.6 (12.8) 0.57 (0.45–0.9)a 0 – –
Health2010a All 642 55.6 46.6 (8.2) 0.45 (0.34–0.57)a 0 – –
Inter99a All 5971 50.9 46.1 (7.9) 0.34 (0.23–0.57)a 5.2 Type 2 –
DM 311 37.6 51.0 (7.1) 0.45 (0.34–1.13)a –
Non-DM 5660 51.6 45.9 (7.8) 0.34 (0.23–0.57)a –
Vejle Biobankc DM 1942 38.1 63.4 (8.7) 0.96 (0.54–1.83)a 100 Type 2 –
Stage 2 (replication 1): Europeans
DanFunDa All 7364 47.3 52.1 (13.1) 0.57 (0.57–0.57)a 6.3 Type 2 –
DM 449 43.9 60.4 (8.8) 0.57 (0.57–1.47)a –
Non-DM 6915 62.4 51.4 (13.3) 0.57 (0.57–0.57)a –
Genesis/Genediabb DM 1249 52.2 42.2 (11.9) 0.11 (0.51–1.36)a 100 Type 1 25.6 (10.2)
MDCSa All 2641 56.5 73.0 (5.6) 0.6 (0.4–1.2)a 21 Type 2 –
DM 547 48.3 73.6 (5.4) 0.8 (0.4–2.2)a –
Non-DM 2094 58.6 72.9 (5.6) 0.6 (0.4–1.1)a –
SUMMIT Consortium (diabetes cohorts)
Benedict (Phase A and B)c DM 324 32.7 68.1 (7.7) 17.3 (4.6–55.6)b 100 Type 2 17.2 (7.1)
Cambridgeb DM 245 46.9 23.1 (9.9) 0.78 (0.52–1.71)a 100 Type 1 15.7 (6.5)
Eurodiabb DM 680 50.0 42.5 (9.9) 23.9 (22.6–25.3)b 100 Type 1 24.7 (8.4)
FinnDianeb DM 2840 50.6 43.9 (11.7) 11.0 (5.0–89.6)b 100 Type 1 29.1 (10.0)
GoDarts 1c DM 3530 46.0 67.0 (0.7) 46.1 (38.7–52.6)a 100 Type 2 7.5 (6.0)
GoDarts 2c DM 2805 43.0 66.8 (11.8) 50.5 (40.7–59.3)a 100 Type 2 7.3 (6.2)
SDR (Type1)b DM 598 43.0 48.6 (13.7) 8.6 (4.3–50.4)b 100 Type 1 31.9 (13.3)
SDR (Type2)c DM 1426 41.3 65.6 (10.7) 18.7 (7.2–100.8)b 100 Type 2 14.3 (7.6)
Steno Type 2 Diabetesc DM 295 39.3 61.5 (8.1) 50.5 (13.9–893.0)b 100 Type 2 15.1 (6.8)
Stage 2 (replication 2): Greenlanders
Greenlandersa
(IHIT + B99)
All 2605
(IHIT = 2519;
B99 = 86)
53.7 44.1 (14.5) 0.9 (0.68–1.58)a 8.1 – –
Data for age and diabetes duration are shown as mean ± standard deviation; ACR (mg/mmol)/AER (mg/24 h) are represented as median (interquartile
range). For some studies, AER was converted from μg/min to mg/24 h with a multiplication factor of 1.44 (μg/min × 1.44 =mg/24 h). ACR was
converted from mg/g to mg/mmol by a multiplication factor of 0.113 (mg/g × 0.113 =mg/mmol)
In sample set type, ‘All’ is all the individuals in the cohort (with and without diabetes). These sets are further stratified based on presence or absence of
diabetes. The number of individuals in the phenotyping summary may not match the association summary numbers in actual analyses because genetic
information is missing for some individuals
a Population-based studies
b Type 1 diabetes study
c Type 2 diabetes study
DM, diabetes mellitus (with); Go-DARTS, Genetics of Diabetes Audit and Research in Tayside Scotland; IHIT, Inuit Health in Transition study;
non-DM, without diabetes mellitus; SDR, Scania Diabetes Registry
Diabetologia (2019) 62:292–305 295
implemented to estimate the heterogeneity in effect size across
the participating studies. The proportion of phenotypic vari-
ance (r2 or the coefficient of determination) associated with
the top SNP was estimated through a linear regression model
(trait ~ SNP + covariates) with the covariates age + sex + prin-
cipal components (PCs). METAL software [24] was used for
the meta-analysis and the Rmeta package [25] for constructing
meta-forest plots. Ancestry-specific linkage disequilibrium
(LD) between variants was extracted using the National
Institutes of Health (NIH)-based LDlink database [26].
Replication stage SNPs with p < 5.0 × 10−5 in the discovery
meta-analysis were tested for replication in European (n =
20,759) and Greenlandic (n = 2605) study populations using
a similar approach to that used in the discovery analysis. The
covariates used for each analysis are given in ESM Table 2.
SNPs with imputation quality r2 < 0.3 were not used for rep-
lication (Genesis/Genediab CUBN SNP). Following this, a
fixed-effects meta-analysis using either inverse variance
weighting (wherever possible) or a weighted sum of z scores
was performed. For the IMI-SUMMIT Consortium, no effect
sizes or standard errors were available in the summary results.
Hence, we performed the replication meta-analysis for the
KCNK5 rs10947789 and LMX1B rs140177498 SNPs, for
which the IMI-SUMMIT Consortium contributed data, by
using the weighted sum of z scores. Replication meta-
analysis with pBonferroni = 0.017 (three SNPs) was considered
significant.
Combined meta-analysis The combined meta-analysis was
performed with all individuals of European ancestry (Eur)
followed by pooling with Greenlandic data (Eur–GL).
Any SNP with preplication < 0.017 and pmeta_Eur/Eur–GL <
5.0 × 10−8 was considered overall significant.
Diabetes-stratified analysis Diabetes-stratified SNP–
albuminuria association (for index SNPs) was assessed in
the discovery set (with diabetes, n = 3896; non-diabetes, n =
9330) after pooling individual genotype data on all partici-
pants and verified through an interaction regression model
(trait ~ SNP + diabetes_status + [SNP×diabetes_status] +
age + sex + cohort + PC1–PC4).
Conditional analyses Conditional analyses for novel SNPs
identified in known loci (and/or in low LD, r2 < 0.01) were
performed to determine if the signal was independent. The
following linear model was used: trait ~ top identified SNP
+ secondary known SNP + sex + age + PCs. If the top SNP
retained the association estimates and p value it was consid-
ered an independent signal.
Gene-aggregate tests Gene-based multi-marker association
testing for rare and common exonic and intragenic variants
(after removing monomorphic variants) was performed using
the Meta Analysis for SNP–set (sequence) kernel association
test (MetaSKAT) R package [27]. SNPs were filtered based on
their annotation status in the Genome Variation Server (GVS:
SeattleSeq Annotation 138/hg19), where SNPs belonging to
the following categories were taken forward to the gene-based
analyses: missense, missense-near-splice, splice-3, splice-5,
coding-synonymous, stop-gained, stop-gained-near-splice,
stop-lost, stop-lost-near-splice, untranslated region (UTR)-3,
UTR-5 and intronic. Intergenic variants or singletons that did
not fall under the annotated gene sets were removed, with
18,026 valid gene sets remaining.
At the study-specific level, the gene-based analyses were
performed against the null model (using SKAT-O method)
[27], accounting for sex and ten PCs, generating SKATobjects
individually for each cohort with available genotyped data
(discovery + MDCS study, six studies) which were then
meta-analysed in a single stage to incorporate maximum pow-
er for testing the rare variants cumulatively.
The meta-analysis of the summary-level score statistics was
run using the Hom-Meta-SKAT-O ‘optimal’ method, which
assumes that different studies share the same causal variant,
weighting them equally. A Bonferroni threshold (padjusted <
2.7 × 10−6) based on 18,026 annotated gene sets was used.
Additional SNP–trait associations We examined the associa-
tions of the exome-wide significant index SNPs with type 2
diabetes risk and kidney function (eGFR) in the discovery set.
The Pheno Scanner database (www.phenoscanner.medschl.
cam.ac.uk/phenoscanner), comprising publicly available results
for GWASs and expression quantitative trait loci (eQTL) studies
[28], as well as the GWAS summary results for type 2 diabetes
from the DIAbetes Genetics Replication And Meta-analysis
(DIAGRAM) consortium, were also accessed to mine known
SNP–trait associations for the index SNPs.
SNP functionality prediction We used the Combined
Annotation Dependent Depletion (CADD) database to predict
variants as per their functional categories (deleterious, disease
causal, pathogenicity) through integratingmultiple annotations
into one metric [29]. A scaled CADD or C score/PHRED
[−10 × log10(rank/total)] is a ranking for a variant relative to
all possible substitutions of the human genome (8.6 × 109).
Results
Albuminuria ExWAS
Discovery stage In the discovery stage meta-analysis, three
independent SNPs, including two rare variants (MAF <1%)
in CUBN and LMX1B and a common variant in KCNK5,
attained pdiscovery < 5.0 × 10
−5 (Table 2). The Manhattan, QQ
296 Diabetologia (2019) 62:292–305
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and LocusZoom (http://locuszoom.sph.umich.edu//) plots for
the discovery meta-analysis are shown in Fig. 1, ESM Fig. 1
and Figs 2 and 3 and genotype-stratified study characteristics
are given in ESM Table 3.
The CUBN rs141640975 is a rare (MAF 0. 83%) missense
(A1690V) SNP with the A allele associated with increased
albuminuria (β = 0.25; pdiscovery = 1.2 × 10
−5). Genotype vs
mean albuminuria levels for the CUBN rs141640975 are
shown in ESM Fig. 2 (levels for KCNK5 and LMX1B SNPs
are shown in ESM Figs 3, 4, respectively), whereas a forest
plot depicting the effect estimates for each study in the
discovery meta-analysis is shown in ESM Fig. 5. The
KCNK5 (which encodes potassium two-pore domain channel
subfamily K member 5) common (MAF 23%) intronic
SNP rs10947789 C allele and the LMX1B (encoding LIM
homeobox transcription factor 1 β) rare (MAF 0.89%)
intronic SNP rs140177498 T allele associated with increased
albuminuria (s10947789, β = 0.05, pdiscovery = 1.6 × 10
−5;
ESM Fig. 6; rs140177498, β = 0.26, pdiscovery = 8.7 × 10
−6;
ESM Fig. 7). Systolic BP-adjusted associations are shown in
ESM Table 4.
Replication stage Replication of the three SNPs was sought in
up to 20,759 individuals (with diabetes, n = 11,976; without
diabetes, n = 8783).
TheCUBN rs141640975 replicated strongly (nreplication_CUBN
= 9742; preplication = 2.8 × 10
−7), while the KCNK5 rs10947789
was close (nreplication_KCNK5 = 20,757; preplication = 0.03). The
LMX1B rs140177498 did not replicate (nreplication_LMX1B =
13,233; preplication = 0.43) (Table 2) and was not analysed
further, whereas we continued to look into KCNK5.
Combined meta-analysis The combined meta-analysis (dis-
covery + replication) comprised 33,985 European individuals
while the combined European–Greenland group comprised
36,590 individuals (Table 2). Only the KCNK5 SNP was
available in the Greenlandic Illumina Metabochip data, and
here theKCNK5 rs10947789 C allele had a frequency of 45%.
The CUBN rs141640975 remained significant overall after
the Eur meta-analysis (pmeta_Eur = 1.3 × 10
−11) while the
KCNK5 SNP was non-significant with pmeta_Eur–GL = 9.1 ×
10−6 in the Eur–GLmeta-analysis (Table 2). The overall study
design for single SNP testing is shown in Fig. 3.
Diabetes-stratified association
The effect estimates of CUBN rs141640975 were more than
threefold higher in the type 2 diabetes group (β = 0.69; p =
2.0 × 10−5; ESM Fig. 8) in comparison with the non-diabetes
group (β = 0.20; p = 0.002; ESM Fig. 9) with a significant
interaction based on diabetes status (pinteraction = 7.0 × 10
−4)
(Fig. 4). No significant interaction was observed for the
KCNK5 SNP (pinteraction = 0.077). Replication studies were
not included in this analysis because individual-level geno-
type data were not available for all cohorts.
Conditional analyses
Conditional analysis for the identified CUBN rare variant
rs141640975 (GRCh37.p13 position: 16,992,011, MAF
0.83%) was carried out for the known CUBN common SNP
rs1801239 (GRCh37.p13 position 16,919,052, MAF 10%),
which occurs at a distance of ~73 kbp (LD r2 = 0.0002, D′ =
5
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1.0). The effect estimates for the novel variant rs141640975 did
not change before (prs141640975 = 8.8 × 10
−7, β = 0.33) or after
(prs141640975_condition = 8.5 × 10
−7, β = 0.33) conditioning with
the known CUBN SNP rs1801239 (prs1801239 = 0.0002,
β = 0.05), which is also in LD with another reported SNP
rs17343073 (LD r2 = 0.92, D′ = 1.0). Similar conditioning for
other known CUBN common SNPs (rs6602163/rs10795433)
was performed in the same or proxy SNP (LD, r2 ≥ 0.6, ESM
Table 5).
Power calculations
We performed power calculations for the single SNP analyses
using the Genetic Association Study (GAS) power calculator
for GWAS [30]. For the rare variant (rs141640975), assuming
an additive disease model, α = 5 × 10−8, n~33,000,
MAF~1% and relative risk ~ 1.5, with disease prevalence =
0.15, the expected power was 81%. For the common variant
(rs10947789) α = 5 × 10−8, n~33,000, MAF ~ 23% and rel-
ative risk ~ 1.1, the expected power was 62%.
Gene-aggregate tests
Applying the Hom-O-SKATMeta (weighted) optimal test from
six studies comprising a total of 15,867 individuals, we identi-
fied three genes HES1 (p = 3.7 × 10−9) in chromosome 3,
CDC73 (p = 6.4 × 10−9) in chromosome 1 and GRM5 (p =
1.6 × 10−6) in chromosome 11 (Table 3) surviving Bonferroni
correction (pBonferroni < 2.7 × 10
−6, 18,026 gene sets).
Association results for individual SNPs included in the gene-
aggregate tests for these three genes are shown in ESMTable 6,
whereas the overall analysis design is shown in ESM Fig. 10.
Additional SNP–trait associations
The CUBN rs141640975 A allele was not associated with
type 2 diabetes risk in the discovery set (p > 0.05) or in the
DIAGRAM Consortium summary results (p > 0.05 in
models unadjusted and adjusted for BMI; ESM Table 7).
However, the A allele showed a nominally significant as-
sociation with increased eGFR (p = 0.04, β = 0.026) within
the discovery set (ESM Table 7).
The publicly available report suggests that the CUBN
rare SNP A allele is associated with reduced serum creati-
nine levels in a blood-based metabolomics study (p = 0.014,
β = −0.28).
TheKCNK5 rs10947789 C allele associated with increased
urinary ACR (β = 0.025, p = 5.6 × 10−4) in CKD Genetics
Consortia-based research. Other KCNK5-associated traits in-
clude myocardial infarction (CARDIoGRAMplusC4D
Consortia, β = −0.059, p = 1.4 × 10−6), visual refractive error
(β = 0.11, p = 0.003) and birthweight (Early Growth Genetics
[EGG] Consortium, β = 0.025, p < 0.007) in addition to
KCNK5 being a GWAS locus for coronary artery disease.
eQTL data suggest rs10947789 C allele-specific gene ex-
pression associations within the adrenal gland (β = 0.51, p =
0
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Fig. 2 (a) Regional plot for CUBN rs141640975 on chromosome 10 (for
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below). (b) Regional plot for KCNK5 rs10947789 on chromosome 6.
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availability of LD data for a SNP. For additional documentation please see
http://locuszoom.sph.umich.edu//
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2.5 × 10−5), subcutaneous adipose tissue (β = 0.34, p: 7.2 ×
10−5), lymphoblastoid cell line (β = 0.03, p = 0.0019) and tib-
ial nerve (β = 0.15, p = 0.002).
Detailed SNP–trait associations with references are docu-
mented in ESM Tables 8–10.
SNP functionality prediction
The CUBN missense SNP rs141640975 was described as
functionally ‘deleterious’ with SIFT, ‘probably damaging’
with PolyPhen and had a CADD (scaled C score) of 24.5.
Discussion
In the combined meta-ExWAS of 33,985 Europeans (five dis-
covery and 12 replication cohorts), we identified one novel
CUBN variant associated with albuminuria levels and exerting
>3.5-fold increased effects among individuals with type 2
diabetes compared with non-diabetic individuals.
Although CUBN is a known locus for albuminuria, the
identified rare missense variant shows independent effects
(with respect to known SNPs in CUBN) that are stronger
within the diabetes vs the non-diabetes group (pinteraction =
7.0 × 10−4). This rare variant explains up to 6.4% of variance
per rare allele (in a model adjusted for age and sex) in albu-
minuria levels (natural log transformed). Also, the gene-based
tests identify three additional genes (HES1, CDC73 and
GRM5) that associate with albuminuria (pBonferroni < 2.7 ×
10−6) in a meta-analysis comprising six Scandinavian cohorts.
There have been a few albuminuria GWASs in the past
decade [10–12, 31], all exploring the common genetic variants
(MAF>5%), but in the current study we examined low-
frequency and rare variants, particularly from the coding re-
gion (exome) of the genome.
While common variants in CUBN have been previously
reported to associate with albuminuria in individuals of
European, African and Hispanic ancestry [10, 32], the rare
missense (A1690V) SNP rs141640975 in CUBN that we
Identify top SNPs for 
replication 
p < 5.0 × 10-5 
Replication (Europeans [Eur]): 12 cohorts
nall: 20,759 (ndm: 11,976; nndm: 8783)
Combined meta-analyses (Eur)
(discovery + replication [Eur]) 
nall: 33,985
(Greenlanders [GL]): 2 cohorts 
nall: 2605
SNPs: 263,894 
(Illumina HumanExome chip 
+ Danish exome sequencing [21])
Association analyses (linear additive model)
Loge albuminuria ~ SNP + covariates
a
Stage 1: Discovery
Albuminuria
(ACR in mg/mmol; AER in mg/24 h) 
5 Danish cohorts: Addition-DK, Health2006, Health2008, Inter99, Vejle Biobank
nall: 13,226 (ndm: 3896; nndm: 9330) 
p < 0.017  
(3 SNPs)
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Fig. 4 ACR levels stratified by CUBN rs141640975 genotype (GG, AG
and AA) and type 2 diabetes status in the discovery cohorts. Diabetes,
with GG n = 3806, with GA n = 66, with AA n = 1; no diabetes, with GG
n = 9270, with GA n = 152, with AA n = 1
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Fig. 3 Study design overview. dm, with diabetes; ndm, without diabetes. acovariates: age, sex, PCs
identified is not in LD with the recently reported CUBN SNPs
rs1801239 (r2LD = 0.0002, D′LD = 1.0) [10] and rs6602163
(r2LD = 0.0008, D′LD = 1.0) [11] for European ancestry. This
is confirmed in the current study through conditional analyses
(rs1801239/rs17343073, pconditional = 8.5 × 10
−7 and
rs6602163/rs10795433, pconditional = 4.9 × 10
−7), with the mi-
nor allele associated with increased albuminuria.
A strong interaction between diabetes status andCUBNmis-
sense rs141640975 observed with respect to albuminuria in the
current study suggests potential clinical implications. Cubilin,
encoded by the CUBN gene, is expressed in the apical brush
border of proximal renal tubule cells and forms a complex with
megalin protein to promote albumin re-uptake [10, 33]. An
important mechanism underlying DKD is tubulointerstitial
damage involving the proximal tubule [4]. A diabetic or
hyperglycaemic state alters the tubular function by augmenting
glomerular hyperfiltration [4, 5], while the proximal tubule may
determine the level of glomerular hyperfiltration through glu-
cose reabsorption [34]. Excess albumin in the urine may be a
consequence of defective tubular reabsorption in diabetic indi-
viduals, which could be protective against DKD by reducing
the reabsorption of glucose. A recent study on diabetic mice
identified a lower expression of cubilin (part of the endocytic
machinery) in the renal cortex and proximal tubule and a cor-
relation between tubular endocytosis dysfunction and higher
urinary excretion of albumin, transferrin and total protein
[35], highlighting the critical role of cubilin and the proximal
tubule in the diabetic state.
As cubilin protein is a co-receptor not only for tubular resorp-
tion but also for the intestinal vitamin B12–intrinsic factor com-
plex,CUBNmutations lead to a hereditary form ofmegaloblastic
anaemia (or Imerslund–Gräsbeck syndrome) characterised by
tubular proteinuria and vitamin B12 malabsorption [36, 37].
Moreover, a recent exome-sequencing study revealed a homozy-
gous frameshift mutation in CUBN associated with the only
cause of proteinuria in affected family members [37]. Despite
CUBN being a disease gene, recent exome-sequencing studies
and related reference databases (ExAC [38]) have shown that
damaging variants are rather frequent in ‘non-diseased’ popula-
tions and are thus well tolerated by humans [38, 39]. On this
basis, it was recently hypothesised that the tubular proteinuria
caused by cubilin deficiency could actually be protective against
tubular overload, seen, for example, in nephrotic syndrome or
even DKD [39]. As CUBN rs141640975 has been associated
with lower serum creatinine (p = 0.014) in a recent meta-
GWAS of circulating metabolites [40] and causes albuminuria
also in the general population group, our study supports the idea
that functional variations in CUBN might not be damaging but
instead protective. TheCADD/SIFT database testing of function-
ality of the non-synonymous SNPs that result in amino acid
changes suggests CUBN rs141640975, with a high C score and
deleterious nature, to be of functional importance. Indeed, we
found that the albuminuria-increasing rs141640975 A allele
was associated with more efficient kidney function in the discov-
ery set (p= 0.04), suggesting it may be protective against DKD.
However, further functional and validation studies are required to
shed light on the potential protective effect of thisCUBN variant.
Although no other SNP was replicated in the single SNP
analyses, the KCNK5 gene was close to the replication threshold
(p= 0.03), though it did not reach the GWAS threshold in the
combined Eur–GL meta-analysis (p= 9.1 × 10−6). KCNK5 is a
known coronary artery disease GWAS locus [41], encoding the
potassium two-pore domain channel subfamily K member 5
protein, which is mainly expressed in the cortical distal tubules
and collecting ducts of the kidney [42]. This protein is highly
sensitive to pH, and functional inactivation may lead to renal
acidosis [43]. Data mining revealed the rs10947789 minor allele
(C) to be associated with increased albuminuria in the CKDGen
Consortia [11], supporting our findings. eQTL-based look-ups
indicate rs10947789 associated stronglywithKCNK5 expression
Table 3 Genes associated with albuminuria through gene-aggregate tests
Gene Chr p value No. SNPs/set Full gene name Alternative gene symbols Gene ID (NCBI)
21 Dec 2017
HES1 3q29 3.7 × 10−9 2 Hes family bHLH transcription factor 1 HHL; HRY; HES-1; bHLHb39 3280
CDC73 1q312 6.4 × 10−9 2 Cell division cycle 73 HYX; FIHP; HPTJT; HRPT1;
HRPT2; C1orf28
79,577
GRM5 11q142–q143 1.6 × 10−6 7 Glutamate metabotropic receptor 5 mGlu5; GPRC1E; MGLUR5;
PPP1R86
2915
All results significant at p < 2.7 × 10−6 , after correction for (Bonferroni’s) multiple testing and are based on six study cohorts (discovery set + MDCS)
Inclusions for gene-aggregate tests are based on annotated exonic or intragenic SNPs, totalling n = 18,026 gene sets examined
Detailed results for the identified genes are available in ESM Table 6
The SKAT-cohort function was used to run each cohort, adjusting for age, sex, PCs + study-specific covariates. Following this, the Meta SKAT function
and Hom-O-SKAT Meta (weighted) model was used to meta-analyse individual cohort data. The rest of the replication studies did not have
data/resources available to run these analyses and therefore could not be incorporated. A brief overview of the gene-aggregate testing is presented in
ESM Fig. 10
Chr, chromosome; ID, identity; no., number
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in the adrenal gland and subcutaneous adipose tissue (p < 8.0 ×
10−5), suggesting a functional role in the kidneys. AlbeitKCNK5
rs10947789 has promising roles with respect to the cardio–renal
axis, the power calculation in the current study (62%) suggests
that the variant has smaller effects; a larger sample size may be
required to validate its association with albuminuria.
The HES1 gene identified through the gene-aggregate tests
is a transcription factor ubiquitously expressed in most organs,
including the kidneys; it has been documented to be involved in
Notch signalling pathways that play a role in renal fibrosis [44],
glomerulosclerosis [45] and other forms of kidney disease [44,
46]. The CDC73 gene is a tumour suppressor gene, mutations
in which have been associated with hyperparathyroidism–jaw
tumour syndrome and familial hyperparathyroidism [47].
Albuminuria is associated with hyperparathyroidism, which is
a complication of CKD [48], and the present findings thus
suggest a plausible link between the two.
GRM5 encodes glutamate metabotropic receptor 5, which
is a G protein-coupled receptor involved in second messenger
signalling. Variants in the metabotropic glutamate receptor
group I pathway, including GRM1 and GRM5, were enriched
in the pathway analysis of a recent albuminuria GWAS among
people with type 1 diabetes from the FinnDiane study [12] (no
individuals overlapped with the current gene-aggregate meta-
analysis). GRM5 is also expressed in podocytes and is associ-
ated with podocyte apoptosis in animals [49] and pharmaco-
logical effects in humans [50].
Albeit the strength of the current study is the identification
and validation of a rare variant with optimal power, more statis-
tical power could have improved KCNK5 validation. Also, test-
ing type 2 diabetes individuals in the discovery stage and includ-
ing type 1 diabetes cohorts in the replication stage may have
introduced some heterogeneity. However, our main finding, the
association of the CUBN rare variant with albuminuria, remains
unaffected as the meta-analysis for this variant only included
type 2 diabetes cohorts because of the lack of genotyping or poor
imputation quality in type 1 diabetes replication cohorts.
Furthermore, the KCNK5 SNP showed the same direction of
effect in both type 1 and type 2 diabetes cohorts, and there was
no significant difference in the association of KCNK5with albu-
minuria between these cohorts (p for heterogeneity [phet] > 0.05).
For the gene-aggregate testing we used six cohorts (having ge-
notype data) in a single-stagemeta-analysis to ensure quality and
maximise statistical power for rare variant analysis.
In summary, we identified a rare coding CUBN variant
implicated in elevated albuminuria levels, especially in indi-
viduals with type 2 diabetes. Further, we identified additional
novel genes associated with albuminuria through an alterna-
tive gene-aggregate approach among Europeans. Our findings
provide fresh insights into the genetic architecture of albumin-
uria and highlight new targets, genes and pathways for the
prevention and treatment of DKD.
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